论文信息 - Ranibizumab port delivery system (RPDS): realising long awaited dream of prolonged VEGF suppression - 字舞流文

Ranibizumab port delivery system (RPDS): realising long awaited dream of prolonged VEGF suppression

C. Regillo | B. Kuppermann | F. Bandello | Ashish Sharma | N. Parachuri | Nilesh Kumar

[1] P. Campochiaro,et al. The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial. , 2019, Ophthalmology.

[2] A. Loewenstein,et al. Biosimilars in ophthalmology: “Is there a big change on the horizon?” , 2018, Clinical ophthalmology.

[3] C. Itsiopoulos,et al. Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration , 2018, Psychology, health & medicine.

[4] Michael Larsen,et al. Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study. , 2018, Ophthalmology.

[5] S R Rufai,et al. A systematic review to assess the ‘treat-and-extend’ dosing regimen for neovascular age-related macular degeneration using ranibizumab , 2017, Eye.

[6] R. Apte,et al. A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration , 2015, British Journal of Ophthalmology.

[7] P. Mitchell,et al. Estimated Cases of Blindness and Visual Impairment from Neovascular Age-Related Macular Degeneration Avoided in Australia by Ranibizumab Treatment , 2014, PloS one.